Enough data support the fact that upon disease progression, NSCLC patients demonstrate an increase in PD-L1+CTCs, while no change or a decrease in PD-L1+CTCs is observed in responding patients [57]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.